BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

Reuters

03 Mar

BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide

March 3 (Reuters) - Takeda Pharmaceutical 4502.T:

PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA
PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE
PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY
PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS
PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL

Source text: ID:nBwbPzjCsa

Further company coverage: 4502.T

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516675680"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516675680\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516675680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516675680","market":"nz","top_or_hot":-1,"title":"BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Takeda Pharmaceutical <span>4502.T</span>:</p><ul><li><p>PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA</p></li><li><p>PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE</p></li><li><p>PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY</p></li><li><p>PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS</p></li><li><p>PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL</p></li></ul><p>Source text: <span>ID:nBwbPzjCsa</span></p><p>Further company coverage: <span>4502.T</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-03 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide</title></head><body><p><span>March 3 (Reuters)</span><span> - </span>Takeda Pharmaceutical <span>4502.T</span>:</p><ul><li><p>PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA</p></li><li><p>PROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDE</p></li><li><p>PROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDY</p></li><li><p>PROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGS</p></li><li><p>PROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIAL</p></li></ul><p>Source text: <span>ID:nBwbPzjCsa</span></p><p>Further company coverage: <span>4502.T</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PL02O:1","article_id":"2516675680","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516675680","pubTimestamp":1741004359,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of RusfertideMarch 3 (Reuters) - Takeda Pharmaceutical 4502.T:PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTGX":"Protagonist Therapeutics Inc"},"translate_title":"简介-Protagonist和武田宣布rusfertide 3期验证研究的积极顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":0.9},"content_text":"BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of RusfertideMarch 3 (Reuters) - Takeda Pharmaceutical 4502.T:PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERAPROTAGONIST THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT WITH HIGHER CLINICAL RESPONDERS ON RUSFERTIDEPROTAGONIST THERAPEUTICS INC - ALL FOUR KEY SECONDARY ENDPOINTS MET IN VERIFY STUDYPROTAGONIST THERAPEUTICS INC - RUSFERTIDE GENERALLY WELL TOLERATED WITH NO NEW SAFETY FINDINGSPROTAGONIST THERAPEUTICS INC - IMPACT ON TAKEDA'S FY2024 FINANCIAL RESULTS IS IMMATERIALSource text: ID:nBwbPzjCsaFurther company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}